Orthostatic Hypotension in Hereditary Transthyretin Amyloidosis: Epidemiology, Diagnosis and Management

Overview

Journal Clin Auton Res

Date 2019 Aug 28

PMID 31452021

Citations 15

Authors

Jose-Alberto Palma

Alejandra Gonzalez-Duarte

Horacio Kaufmann

Affiliations

Soon will be listed here.

Abstract

Purpose: Neurogenic orthostatic hypotension is a prominent and disabling manifestation of autonomic dysfunction in patients with hereditary transthyretin (TTR) amyloidosis affecting an estimated 40-60% of patients, and reducing their quality of life. We reviewed the epidemiology and pathophysiology of neurogenic orthostatic hypotension in patients with hereditary TTR amyloidosis, summarize non-pharmacologic and pharmacological treatment strategies and discuss the impact of novel disease-modifying treatments such as transthyretin stabilizers (diflunisal, tafamidis) and RNA interference agents (patisiran, inotersen).

Methods: Literature review.

Results: Orthostatic hypotension in patients with hereditary transthyretin amyloidosis can be a consequence of heart failure due to amyloid cardiomyopathy or volume depletion due to diarrhea or drug effects. When none of these circumstances are apparent, orthostatic hypotension is usually neurogenic, i.e., caused by impaired norepinephrine release from sympathetic postganglionic neurons, because of neuronal amyloid fibril deposition.

Conclusions: When recognized, neurogenic orthostatic hypotension can be treated. Discontinuation of potentially aggravating medications, patient education and non-pharmacologic approaches should be applied first. Droxidopa (Northera), a synthetic norepinephrine precursor, has shown efficacy in controlled trials of neurogenic orthostatic hypotension in patients with hereditary TTR amyloidosis and is now approved in the US and Asia. Although they may be useful to ameliorate autonomic dysfunction in hereditary TTR amyloidosis, the impact of disease-modifying treatments on neurogenic orthostatic hypotension is still uninvestigated.

Citing Articles

Diagnosis of hereditary transthyretin amyloidosis in patients with suspected chronic inflammatory demyelinating polyneuropathy unresponsive to intravenous immunoglobulins: results of a retrospective study.

Pereon Y, Adams D, Camdessanche J, Chanson J, Cintas P, Magy L Orphanet J Rare Dis. 2025; 20(1):95.

PMID: 40025610 PMC: 11871584. DOI: 10.1186/s13023-025-03589-4.

Cerebral Blood Flow Dynamics in Neurogenic Orthostatic Hypotension: A Systematic Review and Meta-Analysis.

Baker J, Beach P, Ranada S, Patel A, Gewandter J, Tan C Hypertension. 2024; 82(1):106-117.

PMID: 39569517 PMC: 11655256. DOI: 10.1161/HYPERTENSIONAHA.124.23188.

Cardiovascular autonomic failure in hereditary transthyretin amyloidosis and TTR carriers is an early and progressive disease marker.

Chiaro G, Stancanelli C, Koay S, Vichayanrat E, Sander L, Ingle G Clin Auton Res. 2024; 34(3):341-352.

PMID: 38769233 DOI: 10.1007/s10286-024-01038-z.

Autoimmune Autonomic Neuropathy: From Pathogenesis to Diagnosis.

Nakane S, Koike H, Hayashi T, Nakatsuji Y Int J Mol Sci. 2024; 25(4).

PMID: 38396973 PMC: 10889307. DOI: 10.3390/ijms25042296.

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM).

Brito D, Albrecht F, Perez De Arenaza D, Bart N, Better N, Carvajal-Juarez I Glob Heart. 2023; 18(1):59.

PMID: 37901600 PMC: 10607607. DOI: 10.5334/gh.1262.

References

Andrade C . A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952; 75(3):408-27. DOI: 10.1093/brain/75.3.408. View

Jankovic J, Gilden J, Hiner B, Kaufmann H, Brown D, Coghlan C . Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993; 95(1):38-48. DOI: 10.1016/0002-9343(93)90230-m. View

Shimizu H, Ishikawa K, Kobayashi H, Murakami T, Nakazato M, Miura K . [Familial amyloidotic polyneuropathy with a transthyretin variant (Val30-->Leu)]. No To Shinkei. 1996; 48(2):175-8. View

Russo M, Vita G, Stancanelli C, Mazzeo A, Vita G, Messina S . Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy. Neuromuscul Disord. 2016; 26(6):374-7. DOI: 10.1016/j.nmd.2016.03.006. View

Slart R, Glaudemans A, Hazenberg B, Noordzij W . Imaging cardiac innervation in amyloidosis. J Nucl Cardiol. 2017; 26(1):174-187. PMC: 6394628. DOI: 10.1007/s12350-017-1059-9. View

Wieling W, van Lieshout J, van Leeuwen A . Physical manoeuvres that reduce postural hypotension in autonomic failure. Clin Auton Res. 1993; 3(1):57-65. DOI: 10.1007/BF01819146. View

Kaufmann H, Norcliffe-Kaufmann L, Palma J . Droxidopa in neurogenic orthostatic hypotension. Expert Rev Cardiovasc Ther. 2015; 13(8):875-91. PMC: 4509799. DOI: 10.1586/14779072.2015.1057504. View

Algalarrondo V, Antonini T, Theaudin M, Ducot B, Lozeron P, Chemla D . Prediction of long-term survival after liver transplantation for familial transthyretin amyloidosis. J Am Coll Cardiol. 2015; 66(19):2154-2156. DOI: 10.1016/j.jacc.2015.08.870. View

Gupta F, Kremens D, Vernino S, Karabin B . Managing neurogenic orthostatic hypotension in a patient presenting with pure autonomic failure who later developed Parkinson disease. Clin Auton Res. 2017; 27(Suppl 1):9-11. PMC: 5550526. DOI: 10.1007/s10286-017-0428-4. View

10.

Low P, Dyck P, Okazaki H, Kyle R, Fealey R . The splanchnic autonomic outflow in amyloid neuropathy and Tangier disease. Neurology. 1981; 31(4):461-3. DOI: 10.1212/wnl.31.4.461. View

11.

Goodman B, Gupta F . Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy. Clin Auton Res. 2017; 27(Suppl 1):21-23. PMC: 5524855. DOI: 10.1007/s10286-017-0432-8. View

12.

Cho H, Yoon J, Bae M, Lee J, Yang D, Park H . Familial Transthyretin Amyloidosis with Variant Asp38Ala Presenting with Orthostatic Hypotension and Chronic Diarrhea. J Cardiovasc Ultrasound. 2013; 20(4):209-12. PMC: 3542517. DOI: 10.4250/jcu.2012.20.4.209. View

13.

Smit A, Wieling W, Fujimura J, Denq J, Opfer-Gehrking T, Akarriou M . Use of lower abdominal compression to combat orthostatic hypotension in patients with autonomic dysfunction. Clin Auton Res. 2004; 14(3):167-75. DOI: 10.1007/s10286-004-0187-x. View

14.

Mesquita E, Lagoeiro Jorge A, Souza Junior C, Andrade T . Cardiac Amyloidosis and its New Clinical Phenotype: Heart Failure with Preserved Ejection Fraction. Arq Bras Cardiol. 2017; 109(1):71-80. PMC: 5524478. DOI: 10.5935/abc.20170079. View

15.

Perera R, Isola L, Kaufmann H . Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Clin Auton Res. 1995; 5(4):211-3. DOI: 10.1007/BF01824009. View

16.

Tashima K, Ando Y, Terazaki H, Yoshimatsu S, Suhr O, Obayashi K . Outcome of liver transplantation for transthyretin amyloidosis: follow-up of Japanese familial amyloidotic polyneuropathy patients. J Neurol Sci. 1999; 171(1):19-23. DOI: 10.1016/s0022-510x(99)00231-2. View

17.

Benson 2nd M, Turpin J, Lucotte G, Zeldenrust S, Lechevalier B, Benson M . A transthyretin variant (alanine 71) associated with familial amyloidotic polyneuropathy in a French family. J Med Genet. 1993; 30(2):120-2. PMC: 1016267. DOI: 10.1136/jmg.30.2.120. View

18.

Algalarrondo V, Eliahou L, Thierry I, Bouzeman A, Dasoveanu M, Sebag C . Circadian rhythm of blood pressure reflects the severity of cardiac impairment in familial amyloid polyneuropathy. Arch Cardiovasc Dis. 2012; 105(5):281-90. DOI: 10.1016/j.acvd.2012.03.004. View

19.

Jacobson D, McFarlin D, Kane I, Buxbaum J . Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement. Hum Genet. 1992; 89(3):353-6. DOI: 10.1007/BF00220559. View

20.

Fanciulli A, Goebel G, Metzler B, Sprenger F, Poewe W, Wenning G . Elastic Abdominal Binders Attenuate Orthostatic Hypotension in Parkinson's Disease. Mov Disord Clin Pract. 2018; 3(2):156-160. PMC: 6178725. DOI: 10.1002/mdc3.12270. View